Freeline Therapeutics Holdings Plc

NASDAQ FRLN

Download Data

Freeline Therapeutics Holdings Plc Current Liabilities Ratio for the year ending December 31, 2023

Freeline Therapeutics Holdings Plc Current Liabilities Ratio is NA for the year ending December 31, 2023. The current liabilities ratio measures the proportion of a company's current liabilities in relation to its total assets. It is calculated by dividing current liabilities by total assets. This ratio indicates the percentage of a company's total assets that are financed by current liabilities, such as accounts payable and short-term debt. It helps assess the company's short-term solvency and its ability to meet immediate obligations.
  • Freeline Therapeutics Holdings Plc Current Liabilities Ratio for the year ending December 31, 2022 was 0.36, a 143.85% change year over year.
  • Freeline Therapeutics Holdings Plc Current Liabilities Ratio for the year ending December 31, 2021 was 0.15, a 109.28% change year over year.
  • Freeline Therapeutics Holdings Plc Current Liabilities Ratio for the year ending December 31, 2020 was 0.07, a -45.15% change year over year.
  • Freeline Therapeutics Holdings Plc Current Liabilities Ratio for the year ending December 31, 2019 was 0.13, a -55.23% change year over year.
NASDAQ: FRLN

Freeline Therapeutics Holdings Plc

CEO Mr. Michael J. Parini J.D.
IPO Date Aug. 7, 2020
Location United Kingdom
Headquarters Stevenage Bioscience Catalyst, Stevenage, United Kingdom, SG1 2FX
Employees 152
Sector Healthcare
Industry Biotechnology
Description

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies. It develops FLT180a for the treatment of hemophilia B.; FLT201 for the treatment of Type 1 Gaucher disease; and FLT190 for the treatment of Fabry disease. in addition, it has research programs for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.

Similar companies

AVRO

AVROBIO Inc

NA

NA

IMMX

Immix Biopharma Inc

NA

NA

HEPA

Hepion Pharmaceuticals Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email